Daniel De Vos
Overview
Explore the profile of Daniel De Vos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
2668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Z, De Soir S, Glorieux A, Merabishvili M, Knoop C, De Vos D, et al.
Int J Antimicrob Agents
. 2024 Jul;
64(3):107276.
PMID: 39009289
Objectives: Staphylococcus aureus and Pseudomonas aeruginosa co-infections in patients with cystic fibrosis (CF) are associated with disease severity. Their treatment is complicated by biofilm formation in the sticky mucus obstructing...
2.
Pirnay J, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, et al.
Nat Microbiol
. 2024 Jun;
9(6):1434-1453.
PMID: 38834776
In contrast to the many reports of successful real-world cases of personalized bacteriophage therapy (BT), randomized controlled trials of non-personalized bacteriophage products have not produced the expected results. Here we...
3.
De Soir S, Paree H, Kamarudin N, Wagemans J, Lavigne R, Braem A, et al.
Microbiol Spectr
. 2023 Dec;
12(1):e0321923.
PMID: 38084971
Biofilm-related infections are among the most difficult-to-treat infections in all fields of medicine due to their antibiotic tolerance and persistent character. In the field of orthopedics, these biofilms often lead...
4.
Pirnay J, Merabishvili M, De Vos D, Verbeken G
Methods Mol Biol
. 2023 Dec;
2734:89-115.
PMID: 38066364
In this chapter, we discuss production requirements for therapeutic bacteriophage preparations. We review the current regulatory expectancies and focus on pragmatic production processes, implementing relevant controls to ensure the quality,...
5.
Merabishvili M, Pirnay J, De Vos D
Methods Mol Biol
. 2023 Dec;
2734:49-66.
PMID: 38066362
Properly designed bacteriophage therapeutics are the cornerstone for a successful outcome of bacteriophage therapy. Here we present an overview of the different strategies and steps that can be taken to...
6.
Castledine M, Padfield D, Sierocinski P, Soria Pascual J, Hughes A, Makinen L, et al.
Elife
. 2022 Feb;
11.
PMID: 35188102
With rising antibiotic resistance, there has been increasing interest in treating pathogenic bacteria with bacteriophages (phage therapy). One limitation of phage therapy is the ease at which bacteria can evolve...
7.
Mulinganya G, De Vulder A, Bisimwa G, Boelens J, Claeys G, De Keyser K, et al.
PLoS One
. 2021 Oct;
16(10):e0257939.
PMID: 34695126
Background: Bacterial vaginosis (BV) is the most common gynecological condition in women of reproductive age and associated with adverse pregnancy outcomes. In the Democratic Republic of the Congo (DRC), neonatal...
8.
Duyvejonck H, Merabishvili M, Vaneechoutte M, De Soir S, Wright R, Friman V, et al.
Viruses
. 2021 Jun;
13(5).
PMID: 34066841
In Belgium, the incorporation of phages into magistral preparations for human application has been permitted since 2018. The stability of such preparations is of high importance to guarantee quality and...
9.
Lood C, Peeters C, Lamy-Besnier Q, Wagemans J, De Vos D, Proesmans M, et al.
PLoS Pathog
. 2021 Mar;
17(3):e1009418.
PMID: 33720991
Burkholderia multivorans is a member of the Burkholderia cepacia complex (Bcc), notorious for its pathogenicity in persons with cystic fibrosis. Epidemiological surveillance suggests that patients predominantly acquire B. multivorans from...
10.
Mulinganya G, Claeys M, Balolebwami S, Bamuleke B, Mongane J, Boelens J, et al.
Clin Infect Dis
. 2021 Feb;
73(4):e976-e980.
PMID: 33575791
Background: The Democratic Republic of the Congo (DRC) has one of the highest neonatal death rates (between 14% and 28%) in the world. In the DRC, neonatal sepsis causes 15.6%...